Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
A standard of care for pretreated, advanced non–small‐cell lung cancers (NSCLCs), nivolumab has demonstrated long‐term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real‐life long‐term efficacy in a prospective cohort.
Methods
All nivolumab‐tre...
Alternative Titles
Full title
Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b2ddd64664b94102b1cc3e3c92911bf0
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b2ddd64664b94102b1cc3e3c92911bf0
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.3120
